IPCALAB.NS
Ipca Laboratories Limited [IPCALAB.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
IPCALAB.NS Stock Summary
Top 10 Correlated ETFs
IPCALAB.NS
Top 10 Correlated Stocks
IPCALAB.NS
In the News
IPCALAB.NS Financial details
Company Rating
Buy
Market Cap
339.71B
Income
5.64B
Revenue
71.86B
Book val./share
-
Cash/share
-
Dividend
2
Dividend %
0.18%
Employees
16.17K
Optionable
No
Shortable
Yes
Earnings
27 May 2024
P/E
57.54
Forward P/E
-
PEG
-15.91
P/S
4.24
P/B
4.61
P/C
-
P/FCF
-
Quick Ratio
1.04
Current Ratio
2.13
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
22.25
EPS next Y
-
EPS next Q
-
EPS this Y
-46.69%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.08%
Revenue last 5Y
11.08%
Revenue Q/Q
0.93%
EPS Q/Q
23.95%
-
-
-
-
SMA20
13.47%
SMA50
18.15%
SMA100
24.01%
Inst Own
-
Inst Trans
-
ROA
4%
ROE
16%
ROC
0.1%
Gross Margin
65%
Oper. Margin
13%
Profit Margin
7%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
669.8-1348.1
52W High
-0.4%
52W Low
+100.7%
RSI
68.81
Rel Volume
0.22
Avg Volume
563.32K
Volume
121.14K
Perf Week
3.72%
Perf Month
11.99%
Perf Quarter
37.04%
Perf Half Y
37.97%
-
-
-
-
Beta
0.23
-
-
Volatility
9.52%, 68.42%
Prev Close
-0.71%
Price
1342.65
Change
-0.88%
IPCALAB.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 146.14 | 180.27 | 210.87 | 227.29 | 246.13 | |
| Net income per share | 17.61 | 23.98 | 45.01 | 34.85 | 18.58 | |
| Operating cash flow per share | 19.48 | 22.31 | 43.04 | 33.74 | 31.76 | |
| Free cash flow per share | 12.34 | 10.2 | 28.77 | 14.86 | 12.27 | |
| Cash per share | 14.71 | 16.52 | 29.91 | 53.55 | 89.67 | |
| Book value per share | 123.58 | 143.44 | 185.63 | 216.47 | 230.27 | |
| Tangible book value per share | 115.33 | 136.12 | 179.86 | 210.77 | 225.38 | |
| Share holders equity per share | 123.58 | 143.44 | 185.63 | 216.47 | 230.27 | |
| Interest debt per share | 19.13 | 20.43 | 10.82 | 32.1 | 60.18 | |
| Market cap | 122.89B | 176.04B | 241.09B | 270.39B | 205.59B | |
| Enterprise value | 124.72B | 180.46B | 242.09B | 275.71B | 207.82B | |
| P/E ratio | 27.63 | 29.03 | 21.15 | 30.58 | 43.62 | |
| Price to sales ratio | 3.33 | 3.86 | 4.51 | 4.69 | 3.29 | |
| POCF ratio | 24.96 | 31.2 | 22.12 | 31.59 | 25.51 | |
| PFCF ratio | 39.42 | 68.24 | 33.09 | 71.7 | 66.03 | |
| P/B Ratio | 3.94 | 4.85 | 5.13 | 4.92 | 3.52 | |
| PTB ratio | 3.94 | 4.85 | 5.13 | 4.92 | 3.52 | |
| EV to sales | 3.38 | 3.96 | 4.53 | 4.78 | 3.33 | |
| Enterprise value over EBITDA | 16.82 | 18.4 | 15.05 | 20.1 | 19.75 | |
| EV to operating cash flow | 25.34 | 31.98 | 22.21 | 32.21 | 25.79 | |
| EV to free cash flow | 40.01 | 69.95 | 33.23 | 73.11 | 66.75 | |
| Earnings yield | 0.04 | 0.03 | 0.05 | 0.03 | 0.02 | |
| Free cash flow yield | 0.03 | 0.01 | 0.03 | 0.01 | 0.02 | |
| Debt to equity | 0.15 | 0.14 | 0.06 | 0.15 | 0.25 | |
| Debt to assets | 0.1 | 0.1 | 0.04 | 0.11 | 0.17 | |
| Net debt to EBITDA | 0.25 | 0.45 | 0.06 | 0.39 | 0.21 | |
| Current ratio | 2.17 | 2.15 | 3.03 | 3.04 | 2.87 | |
| Interest coverage | 29.04 | 46.85 | 152.68 | 146.28 | 15.44 | |
| Income quality | 0.9 | 0.76 | 0.79 | 0.75 | 1.08 | |
| Dividend Yield | 0 | 0.01 | 0 | 0 | 0 | |
| Payout ratio | 0.03 | 0.2 | 0.09 | 0.11 | 0.22 | |
| Sales general and administrative to revenue | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | |
| Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Intangibles to total assets | 0.05 | 0.04 | 0.03 | 0.03 | 0.02 | |
| Capex to operating cash flow | -0.37 | -0.54 | -0.33 | -0.56 | -0.61 | |
| Capex to revenue | -0.05 | -0.07 | -0.07 | -0.08 | -0.08 | |
| Capex to depreciation | -0.99 | -1.46 | -1.73 | -2.06 | -1.89 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 221.26 | 278.18 | 433.58 | 411.97 | 310.24 | |
| ROIC | 0.12 | 0.15 | 0.22 | 0.13 | 0.06 | |
| Return on tangible assets | 0.1 | 0.12 | 0.19 | 0.12 | 0.06 | |
| Graham Net | 7.68 | 11.71 | 40.08 | 45.16 | 46.5 | |
| Working capital | 12.8B | 15.29B | 23.04B | 29.91B | 33.83B | |
| Tangible asset value | 29.14B | 34.42B | 45.55B | 53.47B | 57.18B | |
| Net current asset value | 9.65B | 12.37B | 20.85B | 23.87B | 24.78B | |
| Invested capital | 0.15 | 0.14 | 0.06 | 0.15 | 0.25 | |
| Average receivables | 8.89B | 10.23B | 10.98B | 11.6B | 11.15B | |
| Average payables | 4.74B | 5.67B | 6.38B | 6.12B | 5.41B | |
| Average inventory | 9.77B | 11.98B | 14.59B | 17.26B | 18.01B | |
| Days sales outstanding | 92.15 | 89.17 | 74.02 | 78.33 | 58 | |
| Days payables outstanding | 148.31 | 130.26 | 134.95 | 96.66 | 83.09 | |
| Days of inventory on hand | 303.37 | 282.61 | 323.08 | 322.02 | 275.88 | |
| Receivables turnover | 3.96 | 4.09 | 4.93 | 4.66 | 6.29 | |
| Payables turnover | 2.46 | 2.8 | 2.7 | 3.78 | 4.39 | |
| Inventory turnover | 1.2 | 1.29 | 1.13 | 1.13 | 1.32 | |
| ROE | 0.14 | 0.17 | 0.24 | 0.16 | 0.08 | |
| Capex per share | -7.15 | -12.11 | -14.27 | -18.88 | -19.49 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 60.93 | 59.6 | 62.6 | 80.2 | 80.91 | |
| Net income per share | 4.25 | 3.02 | 6.42 | 5.72 | 7.09 | |
| Operating cash flow per share | 5.25 | 5.48 | 5.46 | 7.12 | 7.84 | |
| Free cash flow per share | 5.25 | 5.48 | 5.46 | 7.12 | 7.84 | |
| Cash per share | 51.1 | 89.69 | 85.8 | 40.9 | 0 | |
| Book value per share | 230.91 | 230.33 | 233.24 | 242.46 | 0 | |
| Tangible book value per share | 0 | 225.45 | 0 | 288.41 | 0 | |
| Share holders equity per share | 230.91 | 230.33 | 233.24 | 242.46 | 0 | |
| Interest debt per share | 0.43 | 59.13 | 1.24 | 80.11 | 1.32 | |
| Market cap | 213.93B | 205.53B | 188.4B | 237.28B | 283.99B | |
| Enterprise value | 226.89B | 207.77B | 210.16B | 252.82B | 283.99B | |
| P/E ratio | 49.59 | 67.15 | 28.93 | 40.89 | 39.47 | |
| Price to sales ratio | 13.84 | 13.6 | 11.87 | 11.67 | 13.83 | |
| POCF ratio | 160.68 | 147.78 | 135.99 | 131.33 | 142.71 | |
| PFCF ratio | 160.68 | 147.78 | 135.99 | 131.33 | 142.71 | |
| P/B Ratio | 3.65 | 3.52 | 3.18 | 3.86 | 0 | |
| PTB ratio | 3.65 | 3.52 | 3.18 | 3.86 | 0 | |
| EV to sales | 14.68 | 13.74 | 13.24 | 12.43 | 13.83 | |
| Enterprise value over EBITDA | 91.95 | 95.56 | 59.62 | 70.26 | 80.27 | |
| EV to operating cash flow | 170.42 | 149.39 | 151.69 | 139.93 | 142.71 | |
| EV to free cash flow | 170.42 | 149.39 | 151.69 | 139.93 | 142.71 | |
| Earnings yield | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Debt to equity | 0 | 0.25 | 0 | 0.32 | 0 | |
| Debt to assets | 0 | 0.17 | 0 | 0.17 | 0 | |
| Net debt to EBITDA | 5.25 | 1.03 | 6.17 | 4.32 | 0 | |
| Current ratio | 0 | 2.87 | 0 | 2.13 | 0 | |
| Interest coverage | 16.62 | 8.02 | 7.6 | 6.11 | 7.61 | |
| Income quality | 1.23 | 1.82 | 0.85 | 1.25 | 1.11 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0.1 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0.02 | 0 | 0.02 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 148.6 | 125.04 | 183.55 | 176.65 | 0 | |
| ROIC | 0.02 | 0.01 | 0.03 | 0.02 | 0 | |
| Return on tangible assets | 0 | 0.01 | 0 | 0.01 | 0 | |
| Graham Net | 51.1 | 46.51 | 85.8 | -9.24 | 0 | |
| Working capital | 12.97B | 33.83B | 21.76B | 30.33B | 0 | |
| Tangible asset value | 0 | 57.18B | 0 | 73.14B | 0 | |
| Net current asset value | 12.97B | 24.78B | 21.76B | 18.97B | 0 | |
| Invested capital | 0 | 0.25 | 0 | 0.32 | 0 | |
| Average receivables | 5.58B | 4.96B | 4.96B | 8.84B | 8.84B | |
| Average payables | 2.88B | 2.63B | 2.63B | 3.98B | 3.98B | |
| Average inventory | 9.12B | 8.72B | 8.72B | 12.25B | 12.25B | |
| Days sales outstanding | 0 | 59.08 | 0 | 78.25 | 0 | |
| Days payables outstanding | 0 | 79.93 | 0 | 105.61 | 0 | |
| Days of inventory on hand | 0 | 265.41 | 0 | 325.46 | 0 | |
| Receivables turnover | 0 | 1.52 | 0 | 1.15 | 0 | |
| Payables turnover | 0 | 1.13 | 0 | 0.85 | 0 | |
| Inventory turnover | 0 | 0.34 | 0 | 0.28 | 0 | |
| ROE | 0.02 | 0.01 | 0.03 | 0.02 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
IPCALAB.NS Frequently Asked Questions
What is Ipca Laboratories Limited stock symbol ?
Ipca Laboratories Limited is a IN stock and trading under the symbol IPCALAB.NS
What is Ipca Laboratories Limited stock quote today ?
Ipca Laboratories Limited stock price is $1342.65 today.
Is Ipca Laboratories Limited stock public?
Yes, Ipca Laboratories Limited is a publicly traded company.
Something similar
Company Profile
- Volume Average 563.32K
- Market Capitalization 339.71B
- Employee 16.17K
- CEO Mr. Pranay Premchand Godha
- Headquarters Mumbai,IN
- IPO Date 1996-01-01
-
Website
https://www.ipca.com 
Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.
